Merck (MRK) and Eisai (ESAIY) give update on Phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced Renal Cell Carcinoma

Merck and Eisai's update on their Phase 3 trial for a new treatment in advanced Renal Cell Carcinoma could signal significant advancements in the oncology space.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

Kpler's Bakr says "Growing signs that Iran will be sending a delegation to Pakistan, but again there’s no reason to expect a final agreement"

Iran prepares new surprises for the possibility of restarting the war, Tasnim reports; " Iran has always considered the possibility of war to be strong over the past two weeks"

Merck (MRK) and Eisai (ESAIY) give update on Phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced Renal Cell Carcinoma

Northrop Grumman Corp. (NOC) Q1 26 (USD): Adj. EPS 6.14 (exp. 6.07), Revenue 9.9bln (exp. 9.76bln)

Halliburton (HAL) Q1 2026 (USD): adj. EPS 0.55 (exp. 0.50), Revenue 5.4bln (exp. 5.31bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

If the results are positive, it may boost investor confidence in both companies and influence broader market sentiment in pharmaceuticals, particularly within European markets.

Related headlines

The whole workspace, free to try.

Try it free